Cancer-associated muscle loss primarily results from systemic inflammatory responses induced by host-tumor interactions (4), as inflammatory cytokines derived from tumor cells such as IL-6 and TNF-α can impair the differentiation of skeletal muscle cells (5), interfere with insulin signaling, and thereby drive more severe insulin resistance and the degradation of muscle tissue (6). Here, INS is linked to cancer.